Valuation: Gilead Sciences, Inc.

Market Cap 163B 142B 131B 122B 231B 15,518B 235B 1,572B 611B 7,628B 612B 599B 26,285B P/E 2026 *
-46.9x
P/E 2027 * 17.1x
Enterprise Value 173B 151B 139B 129B 245B 16,429B 249B 1,664B 647B 8,076B 648B 634B 27,829B EV / Sales 2026 *
5.66x
EV / Sales 2027 * 5.03x
Free-Float
99.88%
Yield 2026 *
2.47%
Yield 2027 * 2.53%
1 day+4.21%
1 week+6.00%
Current month+3.90%
1 month+2.90%
3 months-6.04%
6 months+7.95%
Current year+6.95%
1 week 124.19
Extreme 124.19
131.58
1 month 121.39
Extreme 121.39
131.66
Current year 116.88
Extreme 116.88
157.29
1 year 107.75
Extreme 107.75
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Date Insider Type Main position Quantity % Market Cap.
06-15Sell

Chief Financial Officer

-3,000 0.0002%
06-15Sell

Executive/Senior Manager

-3,000 0.0002%
06-10Fiscal year

Chief Executive Officer

21,771 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
+0.40%+6.00%+17.72%+70.33% 163B
+3.45%+7.65%+55.77%+158.84% 1,082B
-1.16%+7.42%+69.09%+58.92% 633B
-0.77%+7.37%+36.87%+93.77% 461B
-0.35%+1.85%+31.30%+24.86% 339B
-0.56%+0.96%+41.67%+39.35% 301B
-0.08%+1.30%+32.15%+44.48% 292B
-1.54%+2.81%-25.35%-39.61% 225B
+3.55%+6.05%+26.04%+68.52% 202B
+1.83%+2.75%-3.95%-33.70% 139B
Average +1.16%+4.36%+28.13%+48.58% 383.83B
Weighted average by Cap. +1.07%+5.32%+40.54%+77.51%

Financials

2026 *2027 *
Net sales 30.46B 26.63B 24.47B 22.81B 43.27B 2,901B 43.93B 294B 114B 1,426B 114B 112B 4,913B 32.36B 28.29B 26B 24.23B 45.96B 3,081B 46.66B 312B 121B 1,514B 121B 119B 5,219B
Net income -3.37B -2.95B -2.71B -2.53B -4.79B -321B -4.86B -32.53B -12.65B -158B -12.66B -12.39B -544B 9.55B 8.35B 7.67B 7.15B 13.56B 909B 13.77B 92.09B 35.8B 447B 35.84B 35.07B 1,540B
Net Debt 9.57B 8.36B 7.69B 7.17B 13.59B 911B 13.8B 92.28B 35.88B 448B 35.92B 35.14B 1,543B -96.43M -84.3M -77.47M -72.21M -137M -9.18B -139M -930M -362M -4.51B -362M -354M -15.55B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
02/07/26 $131.27 +4.21% 8,088,800
01/07/26 $125.97 -0.29% 6,654,936
30/06/26 $126.34 +0.01% 7,409,570
29/06/26 $126.33 -1.21% 6,897,708
26/06/26 $127.88 +3.26% 19,908,542
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
131.27USD
Average target price
157.67USD
Spread / Average Target
+20.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock